Cargando…

Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes

Metabolic reprogramming has been described as a hallmark of transformed cancer cells. In this study, we examined the role of the glutamine (Gln) utilization pathway in acute myeloid leukemia (AML) cell lines and primary AML samples. Our results indicate that a subset of AML cell lines is sensitive t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matre, Polina, Velez, Juliana, Jacamo, Rodrigo, Qi, Yuan, Su, Xiaoping, Cai, Tianyu, Chan, Steven M., Lodi, Alessia, Sweeney, Shannon R., Ma, Helen, Davis, Richard Eric, Baran, Natalia, Haferlach, Torsten, Su, Xiaohua, Flores, Elsa Renee, Gonzalez, Doriann, Konoplev, Sergej, Samudio, Ismael, DiNardo, Courtney, Majeti, Ravi, Schimmer, Aaron D., Li, Weiqun, Wang, Taotao, Tiziani, Stefano, Konopleva, Marina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5340236/ https://www.ncbi.nlm.nih.gov/pubmed/27806325 http://dx.doi.org/10.18632/oncotarget.12944

Ejemplares similares

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses
por: Konopleva, Marina, et al.
Publicado: (2023)

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis
por: Hurrish, Katie H., et al.
Publicado: (2023)

Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia
por: Timofeeva, Natalia, et al.
Publicado: (2023)

Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition
por: Saito, Kaori, et al.
Publicado: (2021)

The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy
por: Lukey, Michael J., et al.
Publicado: (2016)

The Role of Glutamine and Glutaminase in Pulmonary Hypertension
por: Wang, Shang, et al.
Publicado: (2022)

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
por: Fuhrmann, Irene, et al.
Publicado: (2022)

Hypoxia Triggers Major Metabolic Changes in AML Cells without Altering Indomethacin-Induced TCA Cycle Deregulation
por: Lodi, Alessia, et al.
Publicado: (2010)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)
por: Konopleva, Marina, et al.
Publicado: (2023)

Deacetylation of Glutaminase by HDAC4 contributes to Lung Cancer Tumorigenesis
por: Wang, Tao, et al.
Publicado: (2022)

P694: RISK ASSESSMENT ACCORDING TO IPSS-M IS SUPERIOR TO AML ELN 2022 RISK CLASSIFICATION IN MDS/AML PATIENTS DEFINED BY ICC – IS AN INCLUSION INTO AML TRIALS JUSTIFIED?
por: Huber, Sandra, et al.
Publicado: (2023)

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
por: Zhang, Qi, et al.
Publicado: (2022)

Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia
por: Zhang, Qi, et al.
Publicado: (2022)

Poster: AML-108: Exogenous Mitochondrial Transfer and Endogenous Mitochondrial Fission Facilitate Resistance to OxPhos Inhibition in AML
por: Tabe, Yoko, et al.
Publicado: (2021)

Targeting glutaminase and mTOR
por: Tanaka, Kazuhiro, et al.
Publicado: (2015)

Phospholipid metabolism regulates AML growth and stemness
por: Xu, Mingjing, et al.
Publicado: (2019)

Gilteritinib Inhibits Glutamine Uptake and Utilization in FLT3-ITD–Positive AML
por: Zavorka Thomas, Megan E., et al.
Publicado: (2021)

Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC
por: Huber, Sandra, et al.
Publicado: (2023)

Upregulation of the Glutaminase II Pathway Contributes to Glutamate Production upon Glutaminase 1 Inhibition in Pancreatic Cancer
por: Udupa, Sunag, et al.
Publicado: (2019)

Dendrimer-conjugated glutaminase inhibitor selectively targets microglial glutaminase in a mouse model of Rett syndrome
por: Khoury, Elizabeth Smith, et al.
Publicado: (2020)

Fatty Acid Metabolism, Bone Marrow Adipocytes, and AML
por: Tabe, Yoko, et al.
Publicado: (2020)

Cigarette smoke exposure accelerates AML progression in FLT3-ITD models
por: Figueroa, Mary, et al.
Publicado: (2023)

Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside–based low-intensity therapy
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy
por: Abbas, Hussein A., et al.
Publicado: (2022)

Mitochondrial GCN5L1 regulates glutaminase acetylation and hepatocellular carcinoma
por: Zhang, Taotao, et al.
Publicado: (2022)

Q-ing tumor glutaminase therapy
por: Stine, Zachary E., et al.
Publicado: (2015)

Governing glutaminolysis by regulation of glutaminase succinylation
por: Ma, Qingxia, et al.
Publicado: (2021)

Targeting glutaminase to starve lymphoma cells
por: Dumontet, Charles
Publicado: (2022)

The Combined Treatment With the FLT3-Inhibitor AC220 and the Complex I Inhibitor IACS-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells
por: Lu, Xiyuan, et al.
Publicado: (2021)

Phosphorylation of glutaminase by PKCε is essential for its enzymatic activity and critically contributes to tumorigenesis
por: Han, Tianyu, et al.
Publicado: (2018)

PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34)
por: Ong, F., et al.
Publicado: (2022)

The ubiquitin-activating enzyme, UBA1, as a novel therapeutic target for AML
por: Barghout, Samir H., et al.
Publicado: (2018)

Overexpression of CD200 is a stem cell-specific mechanism of immune evasion in AML
por: Herbrich, Shelley, et al.
Publicado: (2021)

Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch
por: Lee, Su Yeon, et al.
Publicado: (2016)

An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis
por: Jung, Namyoung, et al.
Publicado: (2015)

Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2
por: Xiao, Daibiao, et al.
Publicado: (2015)

Resistance to energy metabolism - targeted therapy of AML cells residual in the bone marrow microenvironment
por: Tabe, Yoko, et al.
Publicado: (2023)

Bioinformatic profiling identifies the glutaminase to be a potential novel cuproptosis-related biomarker for glioma
por: Ouyang, Zhen, et al.
Publicado: (2022)

Metabolic modulation of neurogenesis: Role of glutaminase-2
por: Salomoni, Paolo
Publicado: (2014)

Targeting hepatic glutaminase activity to ameliorate hyperglycemia
por: Miller, Russell A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_khlnvkgivmoj4e5dveongval7o